News und Analysen
DILIsym Plays Critical Role in Submission to State of California for Common Analgesic Carcinogenicity Risk Assessment
DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software for pharmaceutical safety and efficacy, today announced that the DILIsym
Novocure Announces Agenda for Virtual Research and Development Day
Novocure (NASDAQ: NVCR) today announced the agenda for the company’s virtual Research and Development Day for analysts and investors from 7:30 a.m. to 9:30 a.m. EST on Thursday, November 12, 2020
Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Virtual London Healthcare Conference on
NANOBIOTIX Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
CORRECTION: TIME CHANGE - Lantheus Holdings to Present at November 2020 Investor Conferences
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB, and a global leader in the
Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company, today announced data from an integrated analysis of the AURA-LV and
NanoString Technologies Releases Operating Results for Third Quarter of 2020
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter of 2020.
Northwell Health, Humana Renew Agreement
Northwell Health, New York State’s largest health care provider and private employer, and Humana Inc. (NYSE: HUM), a leading health and well-being company, announced a five-year agreement that will
Transgene And BioInvent Present Data on Next Generation Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB
Transgene Presents E-Poster Outlining Detailed Results from the Phase 1b/2 Trial of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers at SITC 2020
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announced the presentation of the detailed
Humana and The Humana Foundation Commit More Than $2.2 Million to COVID-19 Relief and Hurricane Recovery Efforts in Louisiana
Humana Inc. (NYSE: HUM), a leading health and well-being company, and Humana’s philanthropic arm, The Humana Foundation, have committed more than $2.2 million to COVID-19 relief and hurricane
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the
Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported data from its
EUROIMMUN Launches Quantitative ELISA to Measure SARS-CoV-2 Antibodies Against Viral S1 Protein
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that EUROIMMUN, a PerkinElmer company, has launched the Anti-SARS-CoV-2 QuantiVacTM
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2020 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2020, ended August 31, 2020, after the close of the
Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks
Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced the closing of a new $150 million senior secured
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in
NanoString Launches GeoMx DSP Protein Assays for Next Generation Sequencing
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of GeoMx® DSP Protein Assays for next
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 3, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
NanoString to Present at the 29th Annual Credit Suisse Healthcare Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the company’s management is scheduled to present
Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS)
Pfizer Inc. (NYSE: PFE) announced today positive results from a Phase 3 investigational study evaluating the safety and efficacy of tofacitinib in adults with active ankylosing spondylitis (AS)
Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS)
Pfizer Inc. (NYSE: PFE) announced today positive results from a Phase 3 investigational study evaluating the safety and efficacy of tofacitinib in adults with active ankylosing spondylitis (AS)
Savara Reports Third Quarter 2020 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2020 and provided a business update.
“After recently
Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer